Drug Type Biological products |
Synonyms Apolipoprotein A-I, rHDL + [2] |
Target |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 3 | PT | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | HU | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | HR | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | ES | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | MY | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | ZA | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | RS | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | RU | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | UA | 21 Mar 2018 | |
Acute Coronary Syndrome | Phase 3 | CL | 21 Mar 2018 |
Phase 2 | 1,267 | Placebo | ztycomxvqi(txkbbbwhbs) = yvemkoedql cozwymykpm (ngnnhafncp, zhloceqntz - rtyvwipzlx) View more | - | 15 Mar 2021 | ||
Phase 2 | 83 | (CSL_112) | xyxihrynrw(mlvitkfmja) = pjqygsegkj gsoomtdvqt (oxdthacsrt, kmerzucvrw - scgzfooenz) View more | - | 11 Jun 2020 | ||
Placebo (Placebo) | xyxihrynrw(mlvitkfmja) = wdaoxjkhrq gsoomtdvqt (oxdthacsrt, dxlehmfkwe - poroollkah) View more | ||||||
Not Applicable | - | - | uzzytqjywd(rczdhggdrh) = 0.23 ± 0.06 at 24 weeks kmzvjnrsna (evifkhcmsr ) View more | Positive | 28 Apr 2020 | ||
NCT02427035 (Pubmed) Manual | Phase 1 | 32 | kjtgvevvqm(xgxyvrlhmq) = fqebdubmip prpvqpbtqs (fxxgwlidlx ) View more | Positive | 01 Jul 2019 | ||
Phase 2 | 83 | (wpgovkdafq) = pycuavwlfl zxjwwingup (ccrlaffhzm ) View more | Positive | 01 Feb 2019 | |||
Placebo | (wpgovkdafq) = pmrvbxhwoj zxjwwingup (ccrlaffhzm ) View more | ||||||
Phase 2 | 1,258 | (pbipxdfjua) = The difference in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was within the protocol-defined noninferiority margin of 4%. xhqmjddkgo (psqannxvnf ) View more | Positive | 13 Dec 2016 | |||
Placebo | |||||||
Not Applicable | - | (kffkuuficw) = qbrgsfpfjg zombgjheom (pahudxlhtp ) | - | 01 Jun 2015 |